These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1). Nakatani T; Marui T; Yamamoto T; Hitora T; Akisue T; Kawamoto T; Nagira K; Fujita I; Matsumoto K; Yoshiya S; Kurosaka M Anticancer Res; 2003; 23(3B):2329-33. PubMed ID: 12894511 [TBL] [Abstract][Full Text] [Related]
45. Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression. Kadivar A; Ibrahim Noordin M; Aditya A; Kamalidehghan B; Davoudi ET; Sedghi R; Akbari Javar H Int J Mol Med; 2018 Jul; 42(1):414-424. PubMed ID: 29620139 [TBL] [Abstract][Full Text] [Related]
46. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Chau WK; Ip CK; Mak AS; Lai HC; Wong AS Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058 [TBL] [Abstract][Full Text] [Related]
47. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510 [TBL] [Abstract][Full Text] [Related]
48. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Welker P; Schadendorf D; Artuc M; Grabbe J; Henz BM Br J Cancer; 2000 Apr; 82(8):1453-8. PubMed ID: 10780526 [TBL] [Abstract][Full Text] [Related]
49. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500 [TBL] [Abstract][Full Text] [Related]
50. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Levina V; Marrangoni A; Wang T; Parikh S; Su Y; Herberman R; Lokshin A; Gorelik E Cancer Res; 2010 Jan; 70(1):338-46. PubMed ID: 20028869 [TBL] [Abstract][Full Text] [Related]
56. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Krystal GW; Hines SJ; Organ CP Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594 [TBL] [Abstract][Full Text] [Related]
57. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155 [TBL] [Abstract][Full Text] [Related]
58. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734 [TBL] [Abstract][Full Text] [Related]
59. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer. Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656 [TBL] [Abstract][Full Text] [Related]
60. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]